Steady On For US FDA’s Novel Approvals At Mid-Year, But Another 2023 Is Unlikely

 
• By Bridget Silverman
  
half-way point
CDER’s PERFORMANCE HEADS BACK TO THE MEAN, WHILE CBER STAYS ABOVE AVERAGE. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers